Debate: Optimal Adjuvant Chemotherapy For Resected Pancreatic Cancer - Gemcitabine/Capecitabine

Debate: Optimal adjuvant chemotherapy for resected pancreatic cancer - Gemcitabine/capecitabine

Debate: Optimal adjuvant chemotherapy for resected pancreatic cancer - Gemcitabine/nab-paclitaxel

Debate: Optimal adjuvant therapy for biliary cancer? - Gemcitabine or Capecitabine

Debate: Treatment for Resectable Pancreatic Cancer? - Surgery + Adjuvant Chemotherapy

Debate: Optimal adjuvant therapy for resected pancreatic cancer? - Gem/Nab-Paclitaxel or FOLFIRINOX

Debate: Optimal neoadjuvant strategy in pancreatic cancer - Chemotherapy alone

Controversy Debate 1: Is it justified to move from adjuvant to neo-adjuvant treatment? - Yes

Debate 9: Optimal Adjuvant Therapy in Pancreatic Cancer? - Gemcitabine alone

Resectable Pancreatic Cancer Debate: Total Neoadjuvant vs Adjuvant Therapy - Total Neoadjuvant

#ESMO21 Highlights on gemcitabine vs mFOLFIRINOX in resected pancreatic cancer: PRODIGE 24/CCTG PA6

European Society for Medical Oncology (ESMO)

Debate: How to treat borderline, resectable pancreatic cancer? - Chemotherapy alone

Resectable Pancreatic Cancer Debate: Total Neoadjuvant vs Adjuvant Therapy - Adjuvant Therapy

Optimizing the Continuum of Care for Patients with Pancreatic Cancer: A Case Study-Based Debate

Debate 9: Optimal Adjuvant Therapy in Pancreatic Cancer? - Intensified chemotherapy

Debate: Treatment for Resectable Pancreatic Cancer? - Neo-Adjuvant Chemotherapy

Debate: Optimal neoadjuvant strategy in pancreatic cancer - Preoperative chemotherapy + radiation

ICAHO20 - ASCO Direct™ Highlights - Dr. Andrew Coveler - Pancreatic Cancer

Binaytara Foundation

Gemcitabine monotherapy vs. doublet therapy vs. FOLFIRINOX for metastatic pancreatic adenocarcinoma

Debate: Optimal therapy for patients with resectable pancreatic cancer - Neoadjuvant chemotherapy

Controversy Debate 1: Is it justified to move from adjuvant to neo-adjuvant treatment? - No